• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在发展中国家通过接种疫苗降低轮状病毒相关死亡率所面临的问题。

Issues with reducing the rotavirus-associated mortality by vaccination in developing countries.

作者信息

Naghipour Mohammadreza, Nakagomi Toyoko, Nakagomi Osamu

机构信息

Division of Molecular Epidemiology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan.

出版信息

Vaccine. 2008 Jun 19;26(26):3236-41. doi: 10.1016/j.vaccine.2008.04.004. Epub 2008 Apr 24.

DOI:10.1016/j.vaccine.2008.04.004
PMID:18472196
Abstract

More than 65% of the global rotavirus deaths were estimated to occur in 11 countries in Asia and Africa, claiming 345,000 children less than 5 years of age in 2004. While efficacious rotavirus vaccines are at hand, inequity in health delivery system within and between these countries was found to be the major hurdle against achieving the goal of rotavirus vaccine. When the coverage of currently used vaccines was applied to a rotavirus vaccine, a maximum of 202,550 deaths would be averted. Even if the coverage reached 80%, there would remain 96,841 children dying because of rotavirus diarrhea in these 11 countries. Studies are therefore encouraged to develop comprehensive strategies to resolve inequity in health delivery system enabling the increase in the immunization coverage.

摘要

据估计,全球超过65%的轮状病毒死亡病例发生在亚洲和非洲的11个国家,2004年有34.5万名5岁以下儿童因此死亡。虽然有效的轮状病毒疫苗已经问世,但这些国家内部以及国家之间卫生服务体系的不平等被认为是实现轮状病毒疫苗目标的主要障碍。若将目前使用疫苗的覆盖率应用于轮状病毒疫苗,最多可避免202,550例死亡。即便覆盖率达到80%,这11个国家仍会有96,841名儿童因轮状病毒腹泻死亡。因此,鼓励开展研究以制定全面战略,解决卫生服务体系中的不平等问题,从而提高免疫覆盖率。

相似文献

1
Issues with reducing the rotavirus-associated mortality by vaccination in developing countries.在发展中国家通过接种疫苗降低轮状病毒相关死亡率所面临的问题。
Vaccine. 2008 Jun 19;26(26):3236-41. doi: 10.1016/j.vaccine.2008.04.004. Epub 2008 Apr 24.
2
Rotavirus vaccines: targeting the developing world.轮状病毒疫苗:面向发展中世界
J Infect Dis. 2005 Sep 1;192 Suppl 1:S160-6. doi: 10.1086/431504.
3
Rotavirus vaccines in developing countries: the potential impact, implementation challenges, and remaining questions.发展中国家的轮状病毒疫苗:潜在影响、实施挑战和遗留问题。
Vaccine. 2012 Apr 27;30 Suppl 1:A3-6. doi: 10.1016/j.vaccine.2011.10.007.
4
Remaining issues and challenges for rotavirus vaccine in preventing global childhood diarrheal morbidity and mortality.轮状病毒疫苗在预防全球儿童腹泻发病率和死亡率方面存在的剩余问题和挑战。
Expert Rev Vaccines. 2012 Feb;11(2):211-20. doi: 10.1586/erv.11.184.
5
Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030.轮状病毒疫苗在 GAVI 资格国家的预期健康和经济影响:2011-2030 年。
Vaccine. 2012 Apr 27;30 Suppl 1:A7-14. doi: 10.1016/j.vaccine.2011.12.096.
6
Global mortality associated with rotavirus disease among children in 2004.2004年全球儿童轮状病毒疾病相关死亡率。
J Infect Dis. 2009 Nov 1;200 Suppl 1:S9-S15. doi: 10.1086/605025.
7
Broadening the age restriction for initiating rotavirus vaccination in regions with high rotavirus mortality: benefits of mortality reduction versus risk of fatal intussusception.扩大轮状病毒死亡率高的地区开始接种轮状病毒疫苗的年龄限制:降低死亡率的益处与致命性肠套叠风险的比较
Vaccine. 2009 May 14;27(22):2916-22. doi: 10.1016/j.vaccine.2009.03.016. Epub 2009 Mar 25.
8
How much could rotavirus vaccines reduce diarrhea-associated mortality in northern Ghana? A model to assess impact.轮状病毒疫苗能在多大程度上降低加纳北部与腹泻相关的死亡率?一项评估影响的模型。
J Infect Dis. 2009 Nov 1;200 Suppl 1:S85-91. doi: 10.1086/605062.
9
Rotavirus vaccines and the prevention of hospital-acquired diarrhea in children.轮状病毒疫苗与儿童医院获得性腹泻的预防
Vaccine. 2004 Dec 6;22 Suppl 1:S49-54. doi: 10.1016/j.vaccine.2004.08.017.
10
Distributional impact of rotavirus vaccination in 25 GAVI countries: estimating disparities in benefits and cost-effectiveness.轮状病毒疫苗接种在 25 个 GAVI 国家的分布影响:估计效益和成本效益的差异。
Vaccine. 2012 Apr 27;30 Suppl 1:A15-23. doi: 10.1016/j.vaccine.2012.01.018.

引用本文的文献

1
Surveillance of Human Rotaviruses in Wuhan, China (2019-2022): Whole-Genome Analysis of Emerging DS-1-like G8P[8] Rotavirus.中国武汉人类轮状病毒监测(2019-2022):新兴 DS-1 样 G8P[8]轮状病毒的全基因组分析。
Int J Mol Sci. 2023 Jul 29;24(15):12189. doi: 10.3390/ijms241512189.
2
Management of Diarrhoeal Dehydration in Childhood: A Review for Clinicians in Developing Countries.儿童腹泻性脱水的管理:面向发展中国家临床医生的综述
Front Pediatr. 2018 Feb 23;6:28. doi: 10.3389/fped.2018.00028. eCollection 2018.
3
Reactogenicity and safety of a liquid human rotavirus vaccine (RIX4414) in healthy adults, children and infants in China: randomized, double-blind, placebo-controlled Phase I studies.
在中国健康成年人、儿童和婴儿中液体人轮状病毒疫苗(RIX4414)的反应原性和安全性:随机、双盲、安慰剂对照的 I 期研究。
Hum Vaccin Immunother. 2013 Aug;9(8):1638-42. doi: 10.4161/hv.25076. Epub 2013 Jun 4.
4
G8 rotaviruses with conserved genotype constellations detected in Malawi over 10 years (1997-2007) display frequent gene reassortment among strains co-circulating in humans.在马拉维,10 多年间(1997-2007 年)检测到具有保守基因型组合的 G8 轮状病毒,这些病毒在人群中流行的株间频繁发生基因重配。
J Gen Virol. 2013 Jun;94(Pt 6):1273-1295. doi: 10.1099/vir.0.050625-0. Epub 2013 Feb 13.
5
Molecular characterization of rotavirus strains detected during a clinical trial of a human rotavirus vaccine in Blantyre, Malawi.马拉维布兰太尔地区人类轮状病毒疫苗临床试验中检测到的轮状病毒株的分子特征。
Vaccine. 2012 Apr 27;30 Suppl 1(0 1):A140-51. doi: 10.1016/j.vaccine.2011.09.119.
6
Impact of introducing the pneumococcal and rotavirus vaccines into the routine immunization program in Niger.尼日尔常规免疫规划中引入肺炎球菌和轮状病毒疫苗的影响。
Am J Public Health. 2012 Feb;102(2):269-76. doi: 10.2105/AJPH.2011.300218. Epub 2011 Nov 28.
7
Rotavirus infections and vaccines: burden of illness and potential impact of vaccination.轮状病毒感染和疫苗:疾病负担和疫苗接种的潜在影响。
Paediatr Drugs. 2010 Aug 1;12(4):235-56. doi: 10.2165/11537200-000000000-00000.
8
Innate immune responses to human rotavirus in the neonatal gnotobiotic piglet disease model.先天性免疫反应对人类轮状病毒在新生无菌仔猪疾病模型中的作用。
Immunology. 2010 Oct;131(2):242-56. doi: 10.1111/j.1365-2567.2010.03298.x.
9
Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis.印度使用减毒活人类轮状病毒疫苗(RIX4414)进行大规模疫苗接种的公共卫生影响和成本效益:基于模型的分析
BMJ. 2009 Sep 25;339:b3653. doi: 10.1136/bmj.b3653.